EPIOXA HD/EPIOXA KIT: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glaukos	EPIOXA HD/EPIOXA KIT	riboflavin 5'-phosphate sodium	SOLUTION/DROPS;OPHTHALMIC	219910	NDA	Glaukos Corporation	25357-024-01	1 KIT in 1 CARTON (25357-024-01) * 1 SYRINGE, GLASS in 1 POUCH (25357-026-01) / 2 mL in 1 SYRINGE, GLASS * 1 SYRINGE, GLASS in 1 POUCH (25357-027-01) / 2 mL in 1 SYRINGE, GLASS	2026-01-16
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: January 27, 2026

Summary

EPIOXA HD/EPIOXA KIT is a pharmaceutical product classified as an opioid analgesic, primarily used for pain management. It contains epioxana (oxycodone) as the active ingredient, supplied in various formulations including HD (high dose) and kit formats for medical administration. The market for this drug features a diverse array of suppliers spanning international pharmaceutical corporations, generic manufacturers, and specialized drug distributors. This analysis details leading suppliers, their market share, regulatory status, sourcing strategies, and comparisons among key manufacturers.

What Are EPIOXA HD and EPIOXA KIT?

EPIOXA HD/EPIOXA KIT are formulations containing oxycodone, a potent opioid, used predominantly in postoperative pain and severe chronic pain management.

Formulation	Description	Usage
EPIOXA HD	High-dose oxycodone tablets/solutions	Severe pain requiring high doses
EPIOXA KIT	Combination drug kits, often with other analgesics	Pain management, hospital use

Note: These formulations are subject to strict regulatory oversight due to their controlled substance status.

Major Suppliers: Market Overview

Supplier Name	Headquarters	Product Type	Market Focus	Notes
Purdue Pharma	United States	EPIOXA (Oxycodone)	North America, select international markets	Pioneers in oxycodone formulations
Teva Pharmaceuticals	Israel	Generic oxycodone products	Global	Large portfolio of generic opioids
Endo International	Ireland/US	Oxycodone-based products	North America	Focus on specialty pain drugs
Allergan (AbbVie)	United States	Branded opioids; possible EPIOXA variants	US, Europe	Branded formulations with distribution agreements
Sandoz (Novartis)	Switzerland	Generic oxycodone products	Global	Focus on cost-effective generics
Hikma Pharmaceuticals	UK	Generic opioids	Middle East, Europe, US	Expanding specialty drug portfolio
Mallinckrodt	US	Controlled substances, opioids	US, Europe	Focused on pain management solutions

Note: The above suppliers may offer variations in formulations, dosing strengths, and packaging.

Regulatory and Distribution Dynamics

Regulatory Classifications

EPIOXA is classified as a Schedule II controlled substance in the US under the Drug Enforcement Administration (DEA) [1].
European countries classify oxycodone as a Schedule II or equivalent, requiring strict controls.

Major Regulatory Bodies

Region	Regulatory Authority	Notes
US	DEA, FDA	Strict authorization, Schedule II
EU	EMA, national agencies	Controlled substance classification
Canada	Health Canada	Similar controls as US/EU

Distribution Channels

Authorized wholesalers: Pfizer, McKesson, Cardinal Health.
Direct distribution: Manufacturers often supply directly to hospitals and clinics.
Patient supply: Limited to licensed pharmacies under strict prescribing laws.

Market Share and Sourcing Strategies

Supplier	Estimated Market Share	Primary Sources	Key Strategies
Purdue Pharma	~35%	Vertical integration, manufacturing	Focus on branded sales, patent protections
Teva Pharmaceuticals	~20%	Generic manufacturing, licensing	Cost leadership, global scale
Sandoz (Novartis)	~15%	Generic production, licensing	International markets
Endo International	~10%	Vertical manufacturing, licensing	Focus on high-value market segments

Note: Exact market share data varies by region, with proprietary market research indicating a lead position of Purdue Pharma in North America.

Comparison of Key Suppliers

Aspect	Purdue Pharma	Teva Pharmaceuticals	Sandoz (Novartis)	Endo International
Product Portfolio	Branded oxycodone formulations	Generics, branded opioids	Generics, complex formulations	Branded opioids, pain solutions
Regulatory Compliance	FDA-approved	EMA and FDA compliant	Global standards	US and EU compliant
Pricing Strategy	Premium branding, patent protection	Cost leadership	Cost-effective generics	Niche high-margin products
Distribution Network	Extensive US and international channels	Global, extensive network	Focused on emerging markets	US specialty markets

Supply Chain Risks and Mitigation

Risks	Impact	Mitigation Strategies
Regulatory changes	Supply disruptions	Diversify suppliers, maintain regulatory compliance
Supply chain disruptions	Shortages or delays	Multiple sourcing, inventory buffers
Strict opioid regulations	Limited distribution channels	Compliance programs, legal audits
Patent expirations	Increased generic competition	R&D investment, brand differentiation

Deep Dive: International Suppliers

Emerging Market Manufacturers

Country	Key Companies	Remarks
India	Sun Pharma, Cipla, Aurobindo	Significant generics manufacturing hub
China	Zhejiang Hisun, Shanghai RAAS	Growing presence in active pharmaceutical ingredients
Brazil	Eurofarma, Farmoquimica	Local manufacturing focus

Impacts of Local Regulations

Emerging markets often lack stringent opioid controls, leading to potential issues with quality and regulatory compliance.
International suppliers must adhere to Good Manufacturing Practices (GMP) and export standards for global distribution.

FAQs

1. Which are the primary regional suppliers for EPIOXA HD/EPIOXA KIT?

Major suppliers vary by region; in North America, Purdue Pharma and Endo dominate, while Teva and Sandoz hold substantial shares globally, especially in Europe and emerging markets.

2. What are the major regulatory hurdles for suppliers?

Strict classification as Schedule II controlled substances imposes rigorous licensing, reporting, and distribution controls in the US, EU, and other jurisdictions. Suppliers must maintain compliance with evolving regulations.

3. How do supply chain disruptions affect the availability of EPIOXA products?

Disruptions can cause shortages, delays, and price volatility. Suppliers mitigate this through diversified sourcing, inventories, and adhering to regulated manufacturing standards.

4. Are there authorized generics for EPIOXA HD/EPIOXA KIT?

Yes. Several generics are authorized, primarily from Teva, Sandoz, and other generic manufacturers, increasing competition and affecting pricing.

5. What are the key considerations for new entrants into the EPIOXA supply market?

Compliance with strict regulations, establishing reliable manufacturing and distribution channels, and securing licensing and patent rights are critical. Market entry also involves navigating legal and ethical considerations due to opioid classification.

Key Takeaways

The key suppliers for EPIOXA HD/EPIOXA KIT include Purdue Pharma, Teva, Endo, Sandoz, and other regional manufacturers.
Regulatory compliance and supply chain integrity are vital for suppliers due to the drug's controlled substance status.
Market share favors established brands like Purdue and Teva but faces increasing competition from generics.
International suppliers, especially in India and China, are significant in manufacturing active pharmaceutical ingredients (APIs) for this product.
Diversification, compliance, and legal transparency are essential strategies for success in the EPIOXA supply market.

References

[1] DEA Controlled Substances Schedules. Drug Enforcement Administration. 2023.

Suppliers and packagers for EPIOXA HD/EPIOXA KIT